NEW YORK, Sept. 9, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced the presentation of a pre-clinical poster on TGR-1202 at the 15th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) which is being held in Cologne, Germany.
Help employers find you! Check out all the jobs and post your resume.
